A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

ClinicalTrials.gov ID: NCT07745504

Public ClinicalTrials.gov record NCT07745504. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

Study identification

NCT ID: NCT07745504
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 285 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 3, 2026
Primary completion: May 17, 2027
Completion: Jul 5, 2027
Last update posted: Sep 3, 2026

2026 – 2027

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
Hope Clin Res & Wellness	Conyers	Georgia	30094	Recruiting
East West Med Res Inst	Honolulu	Hawaii	96814	Recruiting
Walgreens - Store 11760	Oak Park	Illinois	60302	Not yet recruiting
Midwest Inst For Clin Res	Indianapolis	Indiana	46260	Recruiting
The Alliance for Multispecialty Research LLC AMR	Lexington	Kentucky	40509	Recruiting
PharmQuest	Greensboro	North Carolina	27408	Recruiting
KDCILM, LLC & Accellacare US, Inc.	Wilmington	North Carolina	28401	Recruiting
Coastal Carolina Res Ctr	North Charleston	South Carolina	29405	Recruiting
Health Res of Hampton Roads	Newport News	Virginia	23606	Recruiting
National Clin Res Inc.	Richmond	Virginia	23294	Recruiting
Selma Medical Associates	Winchester	Virginia	22601-3834	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07745504, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 3, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07745504 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →